Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.Financial_Report.xls
10-K - Arch Therapeutics, Inc.g6510.txt
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R6.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R9.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R3.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R7.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R8.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R5.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R2.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R1.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R4.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R10.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R26.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R16.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R22.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R12.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R24.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R25.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R19.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R17.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R15.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R14.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R11.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R23.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R21.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R27.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R18.htm
EX-32.1 - Arch Therapeutics, Inc.ex32-1.txt
EX-31.1 - Arch Therapeutics, Inc.ex31-1.txt
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R20.htm
v2.4.0.6
Note 8 - Subsequent Events
12 Months Ended
Sep. 30, 2012
Notes  
Note 8 - Subsequent Events

Note 8 – Subsequent Events

 

The Company has evaluated events subsequent to September 30, 2012 to assess the need for potential recognition or disclosure in this report. Such events were evaluated through the date these financial statements were available to be issued. Based upon this evaluation, it was determined that no subsequent events occurred that require recognition or disclosure in the financial statements.